Skip to main content

Table 1 Clinicopathologic variables of patients with early-, middle- or late-onset pancreatic adenocarcinomas reported by the StuDoQ database (2014–2019)

From: Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC

Study cohort

Total

(n = 3011)

EOPC

(n = 110)

MOPC

(n = 1399)

LOPC

(n = 1502)

 

Type of surgery

PD

2412

(80.1%)

DP

599

(19.9%)

Pancreaticoduodenectomy

Distal Pancreatectomy

P value

Onset

n

  

EOPC

83

MOPC

1123

LOPC

1206

EOPC

27

MOPC

276

LOPC

296

 

Age, median (years)

70.5

[62—77]

70.0

[61—77]

46.0

[43—48]

62.0

[57—67]

77.0

[74—80]

46.0

[45—48]

62.0

[57—67]

77.0

[74—80]

 

ASA

        

PPD < 0.05

PDP< 0.001

 1

92

(3.8%)

29

(4.8%)

8

(9.6%)

58

(5.2%)

26

(2.2%)

3

(11.1%)

23

(8.3%)

3

(1.0%)

 

 2

1018

(42.2%)

272

(45.4%)

44

(53.1%)

532

(47.4%)

442

(36.7%)

15

(55.6%)

135

(48.9%)

122

(41.2%)

 

 3

1253

(51.9%)

287

(47.9%)

31

(37.3%)

522 

(46.5%)

700

(58.0%)

9

(33.3%)

115

(41.7%)

163

(55.1%)

 

 4

48

(2.0%)

11

(1.8%)

-

11

(1.0%)

37

(3.1%)

-

3

(1.1%)

8

(2.7%)

 

 5

1

(0.01%)

 

-

-

1

(0.1%)

-

-

-

 

 Unknown

  

-

-

-

-

-

-

 

BMI. median (kg/m2)

24.8

[22.6—27.7]

25.1

[22.6—27.9]

24.9

[21.7—28.1]

25.1

[22.8—28.1]

24.7

[22.4—27.2]

25.3

[20.8—28.7]

25.3

[22.6—28.4]

24.9

[22.6—27.5]

PPD < 0.05

PDP = 0.26

Tumor

Size (cm)

        

PPD = 0.84

PDP = 0.77

 < 2.0

190

(7.9%)

64

(10.7%)

8

(9.6%)

91

(8.1%)

91

(7.5%)

4

(14.8%)

33

(12.0%)

27

(9.1%)

 

 2.0 – 4.0

884

(36.7%)

185

(30.9%)

26

(31.3%)

413

(36.8%)

445

(36.9%)

7

(25.9%)

84

(30.4%)

94

(31.8%)

 

 > 4.0

1337

(55.4%)

347

(57.9%)

49 (59.0%)

619

(55.1%)

669

(55.5%)

16

(59.3%)

159

(57.6%)

172

(58.1%)

 

 Unknown

1

(0.01%)

3

(0.5%)

-

-

1

(0.1%)

-

-

3

(1.0%)

 

Grading

        

PPD = 0.18

PDP = 0.05

 G1

87

(3.6%)

27

(4.5%)

5

(6.0%)

41

(3.7%)

41

(3.4%)

4

(14.8%)

16

(5.8%)

7

(2.4%)

 

 G2

1307

(54.2%)

324

(54.1%)

38

(45.8%)

627

(55.8%)

642

(53.2%)

9

(33.3%)

142

(51.4%)

173

(58.4%)

 

 G3

935

(38.8%)

208

(34.7%)

34

(41.0%)

411

(36.6%)

490

(40.6%)

11

(40.7%)

95

(34.4%)

102

(34.5%)

 

 G4

16

(0.7%)

3

(0.5%)

-

10

(0.9%)

6

(0.5%)

1

(3.7%)

1

(0.4%)

1

(0.3%)

 

 Unknown

67

(2.8%)

37

(6.2%)

6

(7.2%)

34

(3.0%)

27

(2.3%)

2

(7.4%)

22

(8.0%)

13

(4.4%)

 

Lymph node status

        

PPD = 0.10

PDP = 0.11

 Negative

726

(30.1%)

240

(40.1%)

28

(33.7%)

314

(28.0%)

384

(31.9%)

16

(59.3%)

106

(38.4%)

118

(39.9%)

 

 Positive

1685

(69.9%)

358

(59.8%)

55

(66.3%)

809

(72.0%)

821

(68.0%)

11

(40.7%)

170

(61.6%)

177

(59.8%)

 

 Unknown

1

(0.01%)

1

(0.2%)

-

-

1

(0.1%)

-

-

1

(0.3%)

 

Diabetes mellitus

        

PPD < 0.001

PDP = 0.20

 No

1710

(70.9%)

444

(74.1%)

37

(88.0%)

818

(72.8%)

819

(67.9%)

22

(81.5%)

294

(73.9%)

218

(73.6%)

 

 Yes, NIDDM2

327

(13.6%)

84

(14.0%)

2

(2.4%)

127

(11.3%)

198

(16.4%)

3

(11.1%)

32

(11.6%)

49

(16.6%)

 

 Yes, IDDM2

375

(15.5%)

71

(11.9%)

8

(9.6%)

178

(15.9%)

189

(15.7%)

2

(7.4%)

40

(14.5%)

29

(9.8%)

 

 Unknown

-

-

-

-

-

-

-

-

 

Preop Bilirubin, median (mg/dl)

1.9

[0.6—8.5]

0.5

[0.3 -0.7]

1.6

[0.6—7.3]

1.6

[0.5—8.7]

2.2

[0.7—8.5]

0.5

[0.2—0.6]

0.5

[0.3—0.6]

0.5

[0.4—0.7]

PPD < 0.05

PDP< 0.05

 Unknown

176

(7.3%)

47

(7.8%)

5

(6.0%)

85

(7.6%)

86

(7.1%)

1

(3.7%)

26

(9.4%)

20

(6.8%)

 

Preop Tumor marker

         

 CEA, Median (ng/ml)

3.1

[1.9—5.3]

3.0

[1.8—5.4]

2.8

[1.4—4.0]

3.1

[1.9 -5.2]

3.1

[2.0 -5.4]

2.0

[1.7 -4.2]

2.9

[1.9 -4.9]

3.1

[1.8—6.8]

PPD = 0.14

PDP = 0.19

 Unknown

638

(26.5%)

164

(27.4%)

19

(22.9%)

292

(26.0%)

327

(27.1%)

7

(25.9%)

74

(26.8%)

83

(28.0%)

 

 CA19-9, median (U/ml)

133.0

[32.2—532.8]

76.0

[20.4—412.0]

86.0

[28.4—214.8]

115.1

[28.6—494.7]

158.5

[37.8—649.3]

48.1

[12.9—646.0]

67.1

[17.2—354.0]

92.5

[27.1—488.0]

PPD < 0.001

PDP = 0.18

 Unknown

410

(17.0%)

120

(20.0%)

13

(15.7%)

173

(15.4%)

224

(18.6%)

4

(14.8%)

60

(21.3%)

56

(18.9%)

 

Pancreatic duct width

        

PPD < 0.001

PDP< 0.05

 Normal (< 3mm)

882

(26.6%)

251

(41.9%)

32

(38.6%)

442

(39.4%)

408

(33.8%)

8

(29.6%)

111

(40.2%)

132

(44.6%)

 

 Enlarged (> 3mm)

862

(35.7%)

38

(6.3%)

21

(25.3%)

362

(32.2%)

479

(39.7%)

19

(70.4%)

10

(3.6%)

28

(9.5%)

 

 Unknown

668

(27.7%)

310

(51.8%)

30

(36.1%)

319

(28.4%)

319

(26.5%)

-

155

(56.2%)

136

(45.9%)

 

Pancreatic texture

        

PPD = 0.50

PDP = 0.81

 Soft

885

(36.7%)

276

(46.1%)

23

(27.7%)

411

(36.6%)

451

(37.4%)

11

(40.7%)

127

(46.0%)

138

(46.6%)

 

 Hard

985

(40.8%)

113

(18.9%)

32

(38.6%)

473

(42.1%)

480

(39.8%)

3

(11.1%)

54

(19.6%)

56

(18.9%)

 

 Unknown

542

(22.5%)

210

(35.1%)

28

(33.7%)

239

(21.3%)

275

(22.8%)

13

(48.1%)

95

(34.4%)

102

(34.5%)

 
  1. Baseline characteristics according to PD and DP and according to age group, stratified regarding type of resection (PD vs. DP). Tumor stage and grading derived from postoperative histopathology, pancreatic texture and duct width as evaluated by the surgeon intraoperatively. Continuous data are shown as median, categorial data are shown as absolute (relative). Kruskal—Wallis test, Pearson’s chi square test and Fisher’s exact test used, comparing PD and DP resection within Early-, Middle- and Late-Onset group
  2. PD Pancreaticoduodenectomy, DP Distal pancreatectomy, BMI Body mass index, EOPC early-onset pancreatic cancer, MOPC middle-onset pancreatic cancer, LOPC late-onset pancreatic cancer, CEA Tumor marker carcinoembryonic antigen, CA19-9 Tumor marker carbohydrate antigen 19–9, [] interquartile range
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us